Menu
Login
Home
(current)
Recurring Events
CE Calendar
Evaluations
Enduring Materials
Live Events
CE Applications
Links
Login
Enduring Material
Serum Adiponectin Levels as an Independent Marker of Severity of Psoriasis: A Cross-Sectional Analysis
View Activity Info
Enter Basic User Info
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
1800 Diagonal Road, Suite 360
Alexandria, VA 22314
General Information
Active Dates
Thursday, September 21, 2023 - Sunday, September 21, 2025
Estimated Completion Time
60 minutes
Conference Host
National Psoriasis Foundation
Conference Location
Virtual Conference Room
Conference Name
Journal of Psoriasis and Psoriatic Arthritis
Provider
National Psoriasis Foundation
Link to Content
-
https://journals.sagepub.com/doi/10.1177/24755303231199995
Watch this Lecture Remotely
Objectives
Event Objectives
To learn more about correlations between serum adiponectin levels and the severity of psoriasis
Presentations and Speakers
Serum Adiponectin Levels as an Independent Marker of Severity of Psoriasis: A Cross-Sectional Analysis
Bruce Strober, MD
Available Credits/Points
Credit Designation
The National Psoriasis Foundation designates this enduring material for a maximum of 1
AMA PRA Category 1 Credit
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Psoriasis Foundation designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Description
Adiponectin is an adipokine, having anti-inflammatory properties, the levels of which are reduced in metabolic syndrome. In psoriasis, it plays a preventive role by inhibiting the differentiation and proliferation of keratinocytes and decreasing the levels of the signature cytokine, IL-17. The objective of this research is to find a correlation between serum adiponectin levels and the severity of psoriasis and to compare these levels amongst patients with parameters of metabolic syndrome vs those without it.
Disclosure Statements
Series Disclosures
Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended
Sam Koons, NPF Staff, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
BMS - Consulting - Relationship Has Ended
Event Disclosures
Speakers:
Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended
Commercial Support
This activity is supported by educational grants from Novartis.
Accreditation Statement
The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
Percentage of Correct Responses Required to Pass
0 %
Percentage of Responses Required to Submit
100 %
Last Review Date
9/21/2023
Continue to Enduring Material
Powered By
eeds Privacy and Registration Refund Policy
|
eeds Accessibility Statement